Related Experiment Video
Updated: Mar 3, 2026
06:24
Minimal Erythema Dose MED Testing
Published on: May 28, 2013
43.0K
Does low-dose methotrexate deserve more respect from clinicians?
1At the University of California, Davis, School of Nursing in Sacramento, Calif., Brent Luu is an assistant clinical professor of nursing and George W. Rodway is an associate professor of clinical nursing. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Summary
Low-dose methotrexate errors can be life-threatening. This review highlights methotrexate properties, drug interactions, and best practices to prevent adverse events and reduce medical errors.
Area of Science:
- Pharmacology
- Patient Safety
- Medication Error Prevention
Background:
- Low-dose methotrexate (MTX) is widely used but associated with potentially life-threatening medical errors.
- Preventing adverse events related to MTX remains a significant clinical challenge for healthcare providers.
- Understanding MTX toxicities and drug-drug interactions is crucial for safe prescribing.
Purpose of the Study:
- To review the pharmacological properties of methotrexate.
- To identify common drug-drug interactions associated with methotrexate.
- To highlight best practices for reducing methotrexate-related medication errors.
Main Methods:
- Literature review of methotrexate properties and known drug interactions.
- Analysis of best practices published by the Institute for Safe Medication Practices (ISMP).
Main Results:
- Methotrexate exhibits significant toxicities requiring careful monitoring.
- Several common drug-drug interactions can potentiate methotrexate toxicity.
- ISMP provides actionable guidelines to mitigate MTX prescribing errors.
Conclusions:
- Prescribers must be aware of methotrexate's toxicity profile and interaction risks.
- Adherence to established best practices is essential for minimizing methotrexate-associated adverse events.
- Proactive error prevention strategies are vital for patient safety when prescribing low-dose methotrexate.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
293
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
293
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
614
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
614
01:17Phase II Reactions: Methylation Reactions
828
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
828
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:15Drug Dosage Regimen: Overview
4.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.6K